Morbidity rates of influenza could be greatly reduced due to vaccination.
Introduction
Influenza reappears every season and is caused by circulating influenza type A and type B viruses. These viruses evolve through genetic mutations and resulting antigenic changes, what allows them to evade host immunity. Influenza vaccines have to be updated periodically in order to be effective in the following season. Hence, the constant need for seasonal vaccination. As it takes approximately 6 months to produce influenza vaccines, recommendations need to be done in advance. The World Health Organization (WHO) convenes annual meetings in February and September each year to establish the composition of influenza vaccine for the forthcoming season in the northern and southern hemispheres, respectively (Chambers et al. 2015; WHO 2014a; Webster et al. 2013 
Results
The 2014/2015 influenza epidemic season in Poland started in week 5 (January/ February) of 2015 and continued until week 17 (April) of 2015. The influenza activity was moderate with the highest incidence of influenza-like illness (ILI) at week 10/2015 (March) (Fig. 1) . During this season, 2416 specimens were tested for influenza and influenza-like viruses, of which 21.2 % (n ¼ 513) were positive for influenza. In detail, there were, 34.1 % (n ¼ 175) influenza type B, 14.6 % (75) influenza A/H1N1/pdm09, 22.6 % (n ¼ 116) influenza A/H3N2/, and 28.7 % (n ¼ 147) non-subtyped influenza type A. There was observed a co-circulation of influenza type A and B viruses, with influenza A being the most prevalent one (Fig. 2) .
Infections caused by influenza-like viruses accounted for 11.2 % (n ¼ 270) of tested specimens. Respiratory syncytial virus (RSV) was the other predominant virus, constituting 87.0 % (n ¼ 235) of all ILI cases, followed by sporadic cases of human coronavirus (n ¼ 10, 3.7 %), parainfluenza virus-1 (n ¼ 8, 3.0 %), rhinovirus (n ¼ 6, 2.2 %), adenovirus (n ¼ 5, 1.9 %), and parainfluenza viruses 2 and 3 (n ¼ 3, 1.1 % each (Fig. 3) ).
The highest percentage of influenza and ILI confirmed cases was noted in the 0-4 years The lowest morbidity was observed in the 15-25 years (4.9 %) and 10-14 years age-groups (5.4 %) (Fig. 4) . The verification of specimen testing by VSES demonstrated a complete agreement with the results obtained at the National Influenza Center (Table 1) .
Discussion
In the epidemic seasons 2013/2014 and 2014/ 2015 in Poland, the number of specimens received from primary care physicians was similar, although the percentage of influenza and influenza-like infection confirmations was 10 % higher in the latter season. The 2014/2015 morbidity in children aged 0-4 years was twice as much as it had been in the former epidemic season. The vast majority of infections in this group of children was induced by influenza-like viruses (67.2 %). In both seasons, in the case of influenza-like viruses, the predominant virus was RSV. Infections caused by other respiratory viruses occurred sporadically. Influenza cases were caused mainly by influenza type A (83.2 %). The proportion of influenza B was significantly higher in the 2014/2015 season than that in the previous season where it amounted to 1.2 % of all influenza confirmations (Bednarska et al. 2015) . While comparing data from Poland and Europe, it is apparent that the proportion of circulating viruses of influenza type A and B remains similar. In Europe and the whole world alike, the dominant strain was A/H3N2/, but it co-circulated with influenza A/H1N1/pdm09. The predominance of the A/H3N2/ strain also was noted in Poland, even taking into account the fact that not all the specimens tested within the SENTINEL and non-SENTINEL influenza surveillance were subtyped (Broberg et al. 2015; ECDC/WHO 2015; WHO 2015; Rolfes et al. 2014 ).
In the 2014/2015 season, antigenic drift of the subtype A/H3N2/ decreased the effectiveness of vaccine against influenza. Yet vaccination remains the most effective and the cheapest method of influenza prevention (Broberg et al. 2015) . Since 1968, the Advisory Committee on Immunization Practices (ACIP) recommends trivalent vaccines against influenza. They contain two subtypes of influenza virus A and one lineage of influenza virus type B. It should be emphasized that people, particularly those who receive vaccination every season, substantially enhance their immunological memory. 
